Proactive Investors - Run By Investors For Investors

Lifestyle Delivery Systems' subsidiary Agrotech sees 10,000 seeds planted at its California farms

This first crop planting of 10,000 auto flower seeds will be fully grown in 90 days, the firm said
Cannabis plant
This first crop planting of 10,000 auto flower seeds will be fully grown in 90 days, the Vancouver based company said

Lifestyle Delivery Systems Inc (CSE: LDS), the cannabis technology firm, reported Thursday that subsidiary Agrotech LLC has seen 10,000 seeds planted on its contracted outdoor farms in Sacramento, California.

The two one-acre farms planted the first of four crops for this cultivation season and projections for the farms this season are over 12,000 pounds of biomass.

This first crop planting of 10,000 auto flower seeds will be fully grown in 90 days, the Vancouver based company said in a statement.

"It has been a lot of work getting to this stage and I am excited to see the progress we are making," said Casey Fenwick, president of the company. "This is an exciting time for the company as a whole. This phase opens up a lot of new doors to the products we can sell through our anticipated dispensary and its home delivery service. Not only will it allow us to have more brands to sell, but it will also increase our margins within those brands."

Shares in Canada eased over 2% to $0.42  having earlier advanced over 4%.

Contact Giles at [email protected]

Follow him on Twitter@Gile74

View full LDS profile View Profile

Lifestyle Delivery Systems Timeline

Related Articles

patch
May 19 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use